Why pancreatic cancer trial monitoring is critical in 2026
Pancreatic ductal adenocarcinoma (PDAC) remains one of oncology's hardest challenges — 5-year survival below 13%, resistant to most therapies, and historically starved of effective treatments. That's changing fast. The field is now one of the most active in all of oncology, driven by a convergence of biological insights and new therapeutic modalities.
For competitive intelligence teams, the pancreatic cancer space in 2026 demands constant vigilance:
- KRAS inhibitors — AMG 510 (sotorasib) and MRTX849 (adagrasib) opened the KRAS door in NSCLC. KRAS G12D inhibitors (the dominant PDAC mutation) are now entering trials with multiple programs competing. This is the hottest target in PDAC oncology.
- KRAS ON inhibitors and SOS1 programs — next-generation approaches targeting the KRAS pathway in novel ways
- Stroma-targeting strategies — PEGPH20 failed, but hyaluronidase, CAF-targeting, and ECM remodeling approaches continue
- Bispecific antibodies and ADCs — mesothelin-targeted ADCs (including MSLN × TOPO1) showing early promise
- mRNA vaccines and neoantigen approaches — personalized tumor vaccines for PDAC entering Phase 2
- Neoadjuvant strategies — new combinations for borderline resectable disease changing surgical standards
Track every new PDAC trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.
Start 14-Day Free TrialWhat we monitor for pancreatic cancer
Our system pulls from the ClinicalTrials.gov API every day. For a PDAC watch profile, you can configure alerts for:
- Condition keywords: "pancreatic cancer", "pancreatic ductal adenocarcinoma", "PDAC", "pancreatic neoplasm", "exocrine pancreatic"
- Drug/target keywords: "KRAS G12D", "KRAS G12V", "mesothelin", "stroma", "gemcitabine combination" — any drug or mechanism you're tracking
- Phase filter: Phase 1 for early competitive intelligence, Phase 2/3 for near-term competitive threats
- Sponsor type: Industry only (commercial competitive landscape) or all sponsors including academic
- Status changes: New trials, status updates, enrollment completions, and terminations
The KRAS revolution in pancreatic cancer
KRAS mutations drive approximately 90% of pancreatic cancers, with KRAS G12D being the most prevalent (45% of PDAC). After decades of KRAS being considered "undruggable," the development of covalent KRAS G12C inhibitors opened the floodgates. The race is now on for G12D and pan-KRAS inhibitors.
Key competitive dynamics to monitor:
- Mirati Therapeutics (MRTX1133), Revolution Medicines (RMC-9805 and pan-KRAS), Boehringer Ingelheim — all racing for KRAS G12D dominance
- Combination strategies pairing KRAS inhibitors with MEK, SHP2, or immunotherapy are entering trials rapidly
- ADCs targeting KRAS-mutant cells through surface markers (EGFR, ERBB2) are a parallel track
Monitoring new KRAS-related PDAC trials as they register on ClinicalTrials.gov gives BD teams and investors a 2–6 week head start before conference presentations.
Who uses pancreatic cancer trial monitoring
TrialNotify is designed for professionals who need to track the PDAC clinical landscape without spending hours on ClinicalTrials.gov manually:
- Biotech and pharma BD teams — tracking competitor programs for partnering, acquisition, or internal pipeline decisions
- Oncology investors — buyside and sellside analysts monitoring pipeline readouts and competitive positioning
- CROs and clinical operations — identifying enrollment competition for active pancreatic cancer trials
- Pancreatic cancer patient advocacy organizations — staying current on available trial options for patients
- Academic researchers — monitoring the competitive landscape and identifying collaboration opportunities
Stop monitoring ClinicalTrials.gov manually
Set up your PDAC alert profile in 2 minutes. Daily digest delivered to your inbox. Cancel anytime.
Start Free Trial — No Credit Card for 14 DaysHow TrialNotify works
We run a direct API connection to ClinicalTrials.gov every morning, collecting all new and updated trials. Our matching engine compares each trial against your profile — condition keywords, drug targets, phase, sponsor type, and study status. Only relevant trials reach your inbox.
Your daily digest includes: trial title, phase, sponsor, current status, enrollment target, primary endpoint, and a direct link to the ClinicalTrials.gov record. No noise, no duplicate alerts.
Pricing
Basic — $49/month: 3 disease/keyword profiles, daily digest, ClinicalTrials.gov monitoring. Best for individual analysts.
Professional — $149/month: Unlimited profiles, priority email delivery, phase and sponsor filters, digest frequency options. Best for BD teams.
Team — $299/month: Everything in Professional for up to 5 users. Share profiles across your team.
All plans include a 14-day free trial. Not charged until day 15.